Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11)

Toxicological Sciences

Volumn 136, Issue 2, 2013, Pages 328-343

  Pedersen, Jenny M ^a   Matsson, Pär ^a   Bergström, Christel A S ^a   Hoogstraate, Janet ^b   Norén, Agneta ^a   LeCluyse, Edward L ^c   Artursson, Per ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Biovation Park Telge   (Sweden)

^c HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

Alternatives to animal testing; Biliary excretion; Disposition; Drug induced liver injury; Hepatocytes; In vitro and alternatives; Predictive toxicology; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ATENOLOL; AZATHIOPRINE; BILE SALT EXPORT PUMP; BISOPROLOL; BUDESONIDE; CHLORPROMAZINE; CIMETIDINE; COLECALCIFEROL; CYCLOSPORIN A; FLUTAMIDE; GLIBENCLAMIDE; HALOPERIDOL; IMATINIB; ISRADIPINE; LORATADINE; MIFEPRISTONE; OMEPRAZOLE; PREDNISOLONE; PROTEIN; RITONAVIR; SIMVASTATIN; TAUROCHOLIC ACID; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE; ZOPICLONE;

AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DOSE LIVER FUNCTION RELATION; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG STRUCTURE; FATTY ACID TRANSPORT; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IC 50; IN VITRO STUDY; LIPOPHILICITY; LIVER CLEARANCE; LOW DRUG DOSE; MELANOMA; MEMBRANE VESICLE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; TOXIC HEPATITIS; TREATMENT DURATION;

ALTERNATIVES TO ANIMAL TESTING; BILIARY EXCRETION; DISPOSITION; DRUG INDUCED LIVER INJURY; HEPATOCYTES; IN VITRO AND ALTERNATIVES; PREDICTIVE TOXICOLOGY.; RISK ASSESSMENT;

AGED; ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED;

EID: 84890376710     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft197     Document Type: Article

References (42)

1. Bjornsson, E., and Olsson, R. (2006). Suspected drug-induced liver fatalities reported to the WHO database. Dig. Liver Dis. 38, 33-38.
2. Bleibel, W., Kim, S., D'Silva, K., and Lemmer, E. R. (2007). Drug-induced liver injury: Review article. Dig. Dis. Sci. 52, 2463-2471.
3. Bolton E, Wang Y, Thiessen PA, Bryant SH. (2008). PubChem: Integrated Platform of Small Molecules and Biological Activities. Annual Reports in Computational Chemistry, American Chemical Society, Washington, DC, 4, ch 12.
4. Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., and Tong, W. (2011). FDAapproved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16, 697-703.
5. Dawson, S., Stahl, S., Paul, N., Barber, J., and Kenna, J. G. (2012). In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130-138.
6. Food and Drug Administration. (2009). Guidance for Industry: Drug- Induced Liver Injury: Premarketing Clinical Evaluation. Food and Drug Administration, Silver Spring, MD.
7. Gerloff, T., Stieger, B., Hagenbuch, B., Madon, J., Landmann, L., Roth, J., Hofmann, A. F., and Meier, P. J. (1998). The sister of P-glycoproteinrepresents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273, 10046-10050.
8. Hewitt, N. J., Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007). Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev. 39, 159-234.
9. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.-L., and Karlsson, J. (2007). Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35, 1333-1340.
10. Hirano, M., Maeda, K., Hayashi, H., Kusuhara, H., and Sugiyama, Y. (2005). Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. J. Pharmacol. Exp. Ther. 314, 876-882.
11. Jansen, P. L., Strautnieks, S. S., Jacquemin, E., Hadchouel, M., Sokal, E. M., Hooiveld, G. J., Koning, J. H., De Jager-Krikken, A., Kuipers, F., Stellaard, F., et al. (1999). Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117, 1370-1379.
12. Kis, E., Ioja, E., Nagy, T., Szente, L., Herédi-Szabó, K., and Krajcsi, P. (2009). Effect of membrane cholesterol on BSEP/Bsep activity: Species specificity studies for substrates and inhibitors. Drug Metab. Dispos. 37, 1878-1886.
13. Langmann, T., Mauerer, R., Zahn, A., Moehle, C., Probst, M., Stremmel, W., and Schmitz, G. (2003). Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem. 49, 230-238.
14. Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., and Bor, D. H. (2002). Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220.
15. Lecluyse, E. L., and Alexandre, E. (2010). Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol. Biol. 640, 57-82.
16. Lee, W. M. (2003). Drug-Induced Hepatotoxicity. N. Engl. J. Med. 349, 474-485.
17. Liu, X., LeCluyse, E. L., Brouwer, K. R., Gan, L. S., Lemasters, J. J., Stieger, B., Meier, P. J., and Brouwer, K. L. (1999). Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration. Am. J. Physiol. 277, G12-G21.
18. Lynx, M. D., Bentley, A. T., and McKee, E. E. (2006). 3'-Azido-3'- deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: A possible mechanism of AZT hepatotoxicity. Biochem. Pharmacol. 71, 1342-1348.
19. Mackay, I. R. (1999). Immunological perspectives on chronic hepatitis: Virus infection, autoimmunity and xenobiotics. Hepatogastroenterology 46, 3021-3033.
20. Matsson, P., Englund, G., Ahlin, G., Bergström, C. A., Norinder, U., and Artursson, P. (2007). A global drug inhibition pattern for the human ATPbinding cassette transporter breast cancer resistance protein (ABCG2). J. Pharmacol. Exp. Ther. 323, 19-30.
21. Matsushima, S., Maeda, K., Hayashi, H., Debori, Y., Schinkel, A. H., Schuetz, J. D., Kusuhara, H., and Sugiyama, Y. (2008). Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol. Pharmacol. 73, 1474-1483.
22. Morgan, R. E., Trauner, M., van Staden, C. J., Lee, P. H., Ramachandran, B., Eschenberg, M., Afshari, C. A., Qualls, C. W., Jr, Lightfoot-Dunn, R., and Hamadeh, H. K. (2010). Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485-500.
23. Nakakariya, M., Ono, M., Amano, N., Moriwaki, T., Maeda, K., and Sugiyama, Y. (2012). In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes. Drug Metab. Dispos. 40, 602-609.
24. Ohbuchi, M., Miyata, M., Nagai, D., Shimada, M., Yoshinari, K., and Yamazoe, Y. (2009). Role of enzymatic N-hydroxylation and reduction in flutamide metabolite-induced liver toxicity. Drug Metab. Dispos. 37, 97-105.
25. Opar, A. (2012). Overtaking the DILI Model-T. Nat. Rev. Drug Discov. 11, 585-586.
26. Pauli-Magnus, C., and Meier, P. J. (2006). Hepatobiliary transporters and druginduced cholestasis. Hepatology 44, 778-787.
27. Pauli-Magnus, C., Meier, P. J., and Stieger, B. (2010). Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Semin. Liver Dis. 30, 147-159.
28. Pedersen, J. M., Matsson, P., Bergström, C. A., Norinder, U., Hoogstraate, J., and Artursson, P. (2008). Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51, 3275-3287.
29. Pourahmad, J., Eskandari, M. R., Kaghazi, A., Shaki, F., Shahraki, J., and Fard, J. K. (2012). A new approach on valproic acid induced hepatotoxicity: Involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicol. In Vitro 26, 545-551.
30. Rashid, M., Goldin, R., and Wright, M. (2004). Drugs and the liver. Hosp. Med. 65, 456-461.
31. Russmann, S., Kullak-Ublick, G. A., and Grattagliano, I. (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 16, 3041-3053.
32. Shneider, B. L. (2004). Progressive intrahepatic cholestasis: Mechanisms, diagnosis and therapy. Pediatr. Transplant. 8, 609-612.
33. Smith, C. M., Nolan, C. K., Edwards, M. A., Hatfield, J. B., Stewart, T. W., Ferguson, S. S., Lecluyse, E. L., and Sahi, J. (2012). A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J. Pharm. Sci. 101, 3989-4002.
34. Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A., and Meier, P. J. (2000). Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118(2), 422-30.
35. Strautnieks, S. S., Byrne, J. A., Pawlikowska, L., Cebecauerová, D., Rayner, A., Dutton, L., Meier, Y., Antoniou, A., Stieger, B., Arnell, H., et al. (2008). Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134, 1203-1214.
36. Tong, V., Chang, T. K., Chen, J., and Abbott, F. S. (2003). The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. Free Radic. Biol. Med. 34, 1435-1446.
37. U.S. Federal Regulations. (2012). 21 CFR 201.57-Specific Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products Described in § 201.56(B)(1). U.S. Food and Drug Administration, Silver Spring, MD.
38. van Mil, S. W., van der Woerd, W. L., van der Brugge, G., Sturm, E., Jansen, P. L., Bull, L. N., van den Berg, I. E., Berger, R., Houwen, R. H., and Klomp, L. W. (2004). Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 127, 379-384.
39. Warner, D. J., Chen, H., Cantin, L. D., Kenna, J. G., Stahl, S., Walker, C. L., and Noeske, T. (2012). Mitigating the inhibition of human bile salt export pump by drugs: Opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug Metab. Dispos. 40, 2332-2341.
40. Whitington, P. F., Freese, D. K., Alonso, E. M., Schwarzenberg, S. J., and Sharp, H. L. (1994). Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18, 134-141.
41. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.
42. Yabuuchi H., Tanaka K., Maeda M., Takemura M., Oka M., Ohashi R., and Tamai I. (2008). Cloning of the dog bile salt export pump (BSEP; ABCB11) and functional comparison with the human and rat proteins. Biopharm Drug Dispos. 29:441-8.